Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SLDB Stock Forecast 2025-2026
$4.24
Current Price
$330.34M
Market Cap
Buy 12
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to SLDB Price Targets
+371.7%
To High Target of $20.00
+253.8%
To Median Target of $15.00
+112.3%
To Low Target of $9.00
SLDB Price Momentum
+4.4%
1 Week Change
-32.9%
1 Month Change
-12.6%
1 Year Change
+6.0%
Year-to-Date Change
-42.5%
From 52W High of $7.37
+75.9%
From 52W Low of $2.41
📊 TOP ANALYST CALLS
Did SLDB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Solid Biosciences is one of their latest high-conviction picks.
Latest SLDB Stock Price Targets & Analyst Predictions
Based on our analysis of 20 Wall Street analysts, SLDB has a bullish consensus with a median price target of $15.00 (ranging from $9.00 to $20.00). The overall analyst rating is Strong Buy (9.3/10). Currently trading at $4.24, the median forecast implies a 253.8% upside. This outlook is supported by 12 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Arthur He at HC Wainwright & Co., projecting a 371.7% upside. Conversely, the most conservative target is provided by Gena Wang at Barclays, suggesting a 112.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLDB Analyst Ratings
12
Buy
0
Hold
0
Sell
SLDB Price Target Range
Low
$9.00
Average
$15.00
High
$20.00
Current: $4.24
Latest SLDB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLDB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Nov 5, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $11.00 |
| Nov 5, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $14.00 |
| Nov 4, 2025 | Barclays | Gena Wang | Overweight | Maintains | $9.00 |
| Nov 4, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Aug 14, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| Aug 14, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $13.00 |
| Aug 13, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $14.00 |
| Jun 26, 2025 | Citigroup | Yigal Nochomovitz | Buy | Initiates | $14.00 |
| Jun 17, 2025 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $20.00 |
| Jun 6, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $15.00 |
| May 22, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Assumes | $16.00 |
| May 19, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $15.00 |
| May 16, 2025 | Piper Sandler | Biren Amin | Overweight | Maintains | $17.00 |
| May 16, 2025 | Barclays | Gena Wang | Overweight | Maintains | $10.00 |
| May 16, 2025 | Wedbush | Laura Chico | Outperform | Maintains | $17.00 |
| Mar 13, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $11.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $20.00 |
| Mar 7, 2025 | Citizens Capital Markets | Silvan Tuerkcan | Market Outperform | Reiterates | $15.00 |
| Mar 7, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $16.00 |
| Feb 19, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $16.00 |
Solid Biosciences Inc. (SLDB) Competitors
The following stocks are similar to Solid Biosciences based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SLDB
Solid Biosciences
mkt cap
316.15M
Solid Biosciences Inc. (SLDB) Financial Data
Solid Biosciences Inc. has a market capitalization of $330.34M with a P/E ratio of 0.2x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -86.8%.
Valuation Metrics
Market Cap
$330.34M
Enterprise Value
$120.81M
P/E Ratio
0.2x
PEG Ratio
0.0x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+71.5%
Current Ratio
6.7x
Debt/Equity
10.1x
ROE
-86.8%
ROA
-43.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Solid Biosciences Inc. (SLDB) Business Model
About Solid Biosciences Inc.
What They Do
Develops therapies for Duchenne muscular dystrophy.
Business Model
The company focuses on innovative gene therapies to restore functional dystrophin protein in muscle cells affected by DMD. It generates revenue through the advancement of its treatment pipeline, which includes scientific research, clinical development, and potential partnerships with other organizations in the biopharmaceutical sector.
Additional Information
Solid Biosciences operates in a market with a significant unmet medical need, positioning itself to potentially transform patient outcomes for DMD, a rare genetic disorder. The company's emphasis on proprietary technologies and strategic collaborations enhances its capacity for therapeutic delivery and efficacy.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
100
CEO
Mr. Alexander G. Cumbo
Country
United States
IPO Year
2018
Website
www.solidbio.comSolid Biosciences Inc. (SLDB) Latest News & Analysis
Latest News
Quick Summary
Solid Biosciences Inc. (Nasdaq: SLDB) will participate in upcoming investor conferences, focusing on its development of precision genetic medicines for neuromuscular and cardiac diseases.
Why It Matters
Solid Biosciences' participation in investor conferences can enhance visibility, attract potential investors, and signal confidence in its growth strategy, impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The Innovation Passport award speeds up market entry and improves patient access to new, transformative medicines.
Why It Matters
The Innovation Passport award can enhance companies' competitive edge, potentially increasing revenues and market share by speeding up drug approvals and patient access to new treatments.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Solid Biosciences announced positive interim data from the INSPIRE DUCHENNE trial for SGT-003, with 23 participants dosed. They plan to meet with the FDA in H1 2026 regarding potential approval pathways. The company has $236.1 million in cash, extending its runway into H1 2027.
Why It Matters
Solid Biosciences' positive trial results for SGT-003 and plans for FDA discussions signal potential for accelerated approval. Strong interim data boosts confidence and may enhance stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Solid Biosciences Inc. (Nasdaq: SLDB) announced the grant of 26,550 restricted stock units to two new employees, as part of its workforce expansion in developing genetic medicines.
Why It Matters
The grant of RSUs to new hires indicates Solid Biosciences' commitment to attracting talent, which could drive innovation and growth, impacting future performance and stock value.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Solid Biosciences Inc. (Nasdaq: SLDB) will present data on its neuromuscular and cardiac programs at two upcoming international congresses from October 7-12, 2025.
Why It Matters
Solid Biosciences' upcoming presentations at major conferences could signal advancements in their drug pipeline, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting
1 month ago
Quick Summary
Solid Biosciences Inc. (Nasdaq: SLDB) will present updated data from its Phase 1/2 INSPIRE DUCHENNE trial for gene therapy SGT-003 at a conference in Italy from September 26-28, 2025.
Why It Matters
The presentation of updated safety data and biopsy results for SGT-003 could influence Solid Biosciences' stock performance, reflecting market confidence in their gene therapy's potential.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About SLDB Stock
What is Solid Biosciences Inc.'s (SLDB) stock forecast for 2026?
Based on our analysis of 20 Wall Street analysts, Solid Biosciences Inc. (SLDB) has a median price target of $15.00. The highest price target is $20.00 and the lowest is $9.00.
Is SLDB stock a good investment in 2026?
According to current analyst ratings, SLDB has 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $4.24. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLDB stock?
Wall Street analysts predict SLDB stock could reach $15.00 in the next 12 months. This represents a 253.8% increase from the current price of $4.24. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Solid Biosciences Inc.'s business model?
The company focuses on innovative gene therapies to restore functional dystrophin protein in muscle cells affected by DMD. It generates revenue through the advancement of its treatment pipeline, which includes scientific research, clinical development, and potential partnerships with other organizations in the biopharmaceutical sector.
What is the highest forecasted price for SLDB Solid Biosciences Inc.?
The highest price target for SLDB is $20.00 from Arthur He at HC Wainwright & Co., which represents a 371.7% increase from the current price of $4.24.
What is the lowest forecasted price for SLDB Solid Biosciences Inc.?
The lowest price target for SLDB is $9.00 from Gena Wang at Barclays, which represents a 112.3% increase from the current price of $4.24.
What is the overall SLDB consensus from analysts for Solid Biosciences Inc.?
The overall analyst consensus for SLDB is bullish. Out of 20 Wall Street analysts, 12 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are SLDB stock price projections?
Stock price projections, including those for Solid Biosciences Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 15, 2025 4:15 AM UTC